ESR1 and hepatocellular carcinoma: Most importantly, we successfully established two prognostic models for HCC based on independent prognostic IRGs (MMP9, ESR1) that provided prognostic benefit to approximately 15–95% of HCC patients and the predicted OS rates were in good agreement with the actual observed rates.